IMPORTANT SAFETY INFORMATION AND INDICATION
- IZERVAY is contraindicated in patients with ocular or periocular infections and in patients with active
Warnings and Precautions
- Endophthalmitis and Retinal Detachments
- Intravitreal injections, including those with IZERVAY, may be associated with endophthalmitis and
retinal detachments. Proper aseptic injection technique must always be used when administering IZERVAY
in order to minimize the risk of endophthalmitis. Patients should be instructed to report any symptoms
suggestive of endophthalmitis or retinal detachment without delay and should be managed appropriately.
- Neovascular AMD
- In clinical trials, use of IZERVAY was associated with increased rates of neovascular (wet) AMD or
choroidal neovascularization (7% when administered monthly and 4% in the sham group) by Month 12.
Patients receiving IZERVAY should be monitored for signs of neovascular AMD.
- Increase in Intraocular Pressure
- Transient increases in intraocular pressure (IOP) may occur after any intravitreal injection,
including with IZERVAY. Perfusion of the optic nerve head should be monitored following the injection
and managed appropriately.
- Most common adverse reactions (incidence ≥5%) reported in patients receiving IZERVAY were conjunctival
hemorrhage, increased IOP, blurred vision, and neovascular age-related macular degeneration.
IZERVAY™ (avacincaptad pegol intravitreal solution) is indicated for the treatment of geographic
atrophy (GA) secondary to age-related macular degeneration (AMD)
To request medical information or to report an adverse event or product complaint, please call 1-800-707-4479 or send an email to email@example.com.